2016. EULAR Annual Congress – Tofacitinib Versus Biologic Treatments in Moderate to Severe Rheumatoid Arthritis Patients who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

Bergrath E, Wallenstein G, Gerbert R, Gruben D, Makin C. Tofacitinib Versus Biologic Treatments in Moderate to Severe Rheumatoid Arthritis Patients who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. Ann Rheum Dis. 2016;75(Suppl2):726. Presented at: EULAR 2016; June 8-11 2016; London, UK.